Martinsried/Munich – Medigene AG (FSE: MDG1, Prime Standard, SDAX) reported today that an additional European Patent was granted for its dendritic cell (DC) vaccine platform.
The European Patent EP2918673 covers an isolated mature dendritic cell or an isolated population of mature dendritic cells obtainable by a method for in vitro maturation as e.g. disclosed in the patent and has a life-span until 2027. Medigene holds an exclusive license to the patent that was issued to Helmholtz Zentrum München.
Prof. Dolores Schendel, CEO and CSO of Medigene AG, comments: “We are pleased that this new patent adds additional intellectual property protection to Medigene’s DC patent portfolio that already covers our proprietary methods to isolate and mature dendritic cells as well as our DC maturation cocktail.”
Medigene is currently conducting a Phase I/II clinical trial with its DC vaccines in acute myeloid leukemia and has recently published topline interim data of this study (press release from December 19, 2018: bit.ly/2CpWolq).